Key statistics
As of last trade Mirum Pharmaceuticals Inc (08D:FRA) traded at 74.50, -19.46% below its 52-week high of 92.50, set on Feb 23, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 74.50 |
|---|---|
| High | 74.50 |
| Low | 74.50 |
| Bid | 74.50 |
| Offer | 81.00 |
| Previous close | 76.00 |
| Average volume | 26.57 |
|---|---|
| Shares outstanding | 60.34m |
| Free float | 58.82m |
| P/E (TTM) | -- |
| Market cap | 5.57bn USD |
| EPS (TTM) | -0.4783 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 08:55 GMT.
More ▼
Press releases
- Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
- Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
- Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
- Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
More ▼
